Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal CBD in Dravet and Lennox-Gastaut Syndrome
NCT06738732Phase 2Not yet recruiting
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in Dravet syndrome, Lennox-Gastaut syndrome (LGS). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT06738732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738732.